Japan’s OTC Drug Makers Devise Backup For Looming On-Line Sales Ban
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers that specialize in over-the-counter products have devised a new delivery service they hope to use to get around government proposals to ban on-line sales. The Home Medicine Association of Japan would allow buyers to order the same type of drugs and pick them up within three days at nearby stores or pharmacies. Japan's Health Ministry is drafting plans to bar certain OTC drug sales that are not conducted face-to-face with customers. The legislation is required to conform to a pharmaceutical law revision set to take effect in June. Under the new rules, the $276 million on-line drug sales business would be confined to vitamins, intestinal remedies and similar treatments that do not have potentially dangerous side effects. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.